LinkOPH

CHICAGO – PresbyLASIK with adaptive optics before surgery can provide asphericity and improve depth of focus, a speaker told colleagues here.“Visual outcomes after presbyLASIK can really be affected by different optical and [neurological] factors,” Pablo Artal, MD, PhD, said at Refractive Subspecialty Day preceding the American Academy of Ophthalmology meeting. “Adaptive optics, I believe, is a very powerful approach for  presbyLASIK to really optimize the treatment before surgery.”

Read more →

CHICAGO — The benefits of fixated IOLs outweigh the benefits of anterior chamber IOLs due to the increased risk for glaucoma, intraocular inflammation and corneal decompensation seen with anterior chamber IOLs, a surgeon postulated here in a debate of the issue.“We are comfortable with anterior chamber IOLs, and the surgery is simple and effective in our hands,” Jonathan L. Prenner, MD, said during a presentation at the Refractive Surgery Subspecialty Day preceding the American Academy of Ophthalmology meeting. “But, there’s no debate. AC-IOLs are macroincisional, they cause glaucoma, [cystoid macular (Read more...)

CHICAGO — Femtosecond laser-assisted cataract surgery has distinct upsides and downsides, according to two speakers who addressed colleagues here.Burkhard Dick, MD, PhD, and Michael E. Snyder, MD, debated the merits of laser refractive lens surgery during the Refractive Subspecialty Day preceding the American Academy of Ophthalmology meeting. Dick explained the procedure’s pros and Snyder described the cons.

Read more →

CHICAGO — Intrastromal corneal collagen cross-linking combined with small-incision lenticule extraction has shown promising results with a high safety profile, a speaker told colleagues here.During the Refractive Subspecialty Day preceding the American Academy of Ophthalmology meeting, Enrique O. Graue Hernandez, MD, MsC, discussed results of a study using the Aztec Protocol for combined corneal cross-linking (CXL) and small-incision lenticule extraction (smile, Carl Zeiss Meditec).

Read more →

CHICAGO — “Despite identification of risk factors, many ophthalmologists still observe borderline lesions, waiting for growth before initiating treatment of uveal melanomas,” Jerry A. Shields, MD, said in his delivery of the Charles L. Schepens, MD, Lecture here.That trend, however, is not reflected in how cancers in other specialties are managed.

Read more →

Eylea demonstrated superior improvements to mean change in best corrected visual acuity from baseline compared with Avastin and Lucentis injection in a National Institutes of Health-sponsored study, according to a Regeneron press release.The Diabetic Retinopathy Clinical Research Network (DRCR.net) comparative effectiveness study in patients with diabetic macular edema (Protocol T) included 660 patients randomly assigned to treatment with Eylea (aflibercept, Regeneron) 2 mg, Avastin (bevacizumab, Genentech) 1.25 mg, or Lucentis (ranibizumab, Genentech) 0.3 mg. 

Read more →